US4576693075 - Common Stock
INSMED INC
NASDAQ:INSM (3/28/2024, 8:17:39 PM)
After market: 27.13 0 (0%)27.13
-0.19 (-0.7%)
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 736 full-time employees. The company is engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developed for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
INSMED INC
700 Us Highway 202/206
Bridgewater NEW JERSEY 08807
P: 19089779900
CEO: William H. Lewis
Employees: 736
Website: https://insmed.com/
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...
— New survey reveals the prevalence of "Unseenism," which can be described as a social phenomenon where gender and age biases can leave some patients feeling...
Insmed reports Q4 loss, missing EPS estimates by $0.13 but beating revenue expectations by $1.08M.
Here you can normally see the latest stock twits on INSM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: